sorafenib has been researched along with curcumin in 11 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (curcumin) | Trials (curcumin) | Recent Studies (post-2010) (curcumin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 16,336 | 593 | 12,705 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, CF; Liu, HS; Ramesh, C; Su, CL; Tseng, CL; Yao, CF | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE | 1 |
| Banerjee, P; Begum, S; Castellanos, MR; Debata, PR; Genzer, O; Kleiner, MJ; Mata, A | 1 |
| Cao, H; Chen, L; Chen, Y; Gu, W; He, X; Huang, Y; Li, Y; Wang, Y; Xu, M; Yin, Q; Yu, H; Zhang, Z | 1 |
| Chen, W; Lv, Y; Xie, R; Yu, J; Zhang, J | 1 |
| Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF | 1 |
| Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
| Chuang, KL; Dao, AH; Hsu, WH; Huang, CF; Huang, ZY; Liao, SC; Lin, KT; Su, CL; Tsai, TH; Tseng, CL | 1 |
| Bian, Y; Guo, D | 1 |
| Liu, Y; Lv, P; Ma, L; Man, S; Yang, L; Yao, J | 1 |
1 review(s) available for sorafenib and curcumin
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for sorafenib and curcumin
| Article | Year |
|---|---|
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate | 2012 |
9 other study(ies) available for sorafenib and curcumin
| Article | Year |
|---|---|
Using gene expression database to uncover biology functions of 1,4-disubstituted 1,2,3-triazole analogues synthesized via a copper (I)-catalyzed reaction.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Copper; Curcumin; Databases, Genetic; Glycogen Synthase Kinase 3; Humans; Liver Neoplasms; Structure-Activity Relationship; Thiazoles; Triazoles; Urea | 2017 |
Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O: rapid inhibition of Rb phosphorylation as a preamble to cyclin D1 inhibition.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Curcumin; Cyclin D1; Cyclin-Dependent Kinase 4; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Retinoblastoma Protein; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopharmaceutics; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Mice; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Curcumin; Dose-Response Relationship, Drug; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2016 |
A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Curcumin; Diffusion; Drug Synergism; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Niacinamide; Phenylurea Compounds; Polymers; Sorafenib; Treatment Outcome | 2015 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |
Bioactivity Evaluation of a Novel Formulated Curcumin.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Delivery Systems; Humans; Liver Neoplasms; Male; Rats; Rats, Sprague-Dawley; Sorafenib | 2019 |
Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Curcumin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drug Tolerance; Hep G2 Cells; Humans; Injections, Intravenous; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Particle Size; Sorafenib; Surface Properties | 2020 |
Curcumin-enhanced antitumor effects of sorafenib via regulating the metabolism and tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Curcumin; Disease Models, Animal; Drug Synergism; Functional Food; Liver Neoplasms; Mice; Mice, Inbred Strains; Sorafenib; Tumor Microenvironment | 2020 |